Overview
Corporate structure
Attovia Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Attovia Therapeutics, Inc.
- Deep Track Capital, LP Filed SCHEDULE 13G on Attovia Therapeutics, Inc., latest Aug 12, 2026
- Frazier Life Sciences Public Fund, L.P. Filed SCHEDULE 13D on Attovia Therapeutics, Inc., latest Aug 11, 2026
- Attovia Therapeutics, Inc. San Carlos, California
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
Leadership
Who has led Attovia Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.
Board members and other officers (7)
- Chief Scientific OfficerPetter Veiby Aug 4, 2026 to now3
- Chief Business OfficerZaneta Odrowaz Aug 4, 2026 to now4
- Board memberAaron Royston Aug 4, 2026 to now5
- Board memberAngie You Aug 4, 2026 to now6
- Board memberJames N. Topper Aug 4, 2026 to now7
- Board memberJohn W. Smither Aug 4, 2026 to now8
- Board memberMitchell Gold Aug 4, 2026 to now9
Timeline
Calendar
Coming up
- Dec 2, 2026Reports results for the quarter ending Sep/202612
When it reported results
- Sep 2, 2026Reported quarterly or annual results10
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
56 filings to the SEC since October 2021: 1 quarterly reports, 2 major events, 39 insider forms, 2 large holders, 12 other. The latest 20:
- Oct 8, 20264/A EDGAR
- Oct 8, 20263/A EDGAR
- Oct 8, 20264/A EDGAR
- Oct 8, 20263/A EDGAR
- Sep 2, 202610-Q EDGAR
- Sep 2, 20268-K EDGAR
- Aug 28, 20264/A EDGAR
- Aug 28, 2026144 EDGAR
- Aug 28, 20264/A EDGAR
- Aug 13, 20264 EDGAR
- Aug 13, 20264 EDGAR
- Aug 12, 2026SCHEDULE 13G EDGAR
- Aug 11, 2026SCHEDULE 13D EDGAR
- Aug 10, 20264 EDGAR
- Aug 10, 20264 EDGAR
- Aug 7, 20264 EDGAR
- Aug 7, 20264 OWNERSHIP DOCUMENT EDGAR
- Aug 6, 20264 EDGAR
- Aug 6, 20264 EDGAR
- Aug 6, 20264 EDGAR
The 56 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
16 open-market trades by officers, directors and large owners since October 2021: 12 buys and 4 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 6, 2026 | WALSH COLINDirector | Buy | 500,000 | $17.00 | $8.5M | Form 4 |
| Aug 6, 2026 | WALSH COLINDirector | Buy | 500,000 | $17.00 | $8.5M | Form 4 |
| Aug 6, 2026 | FHMLS XI, L.P.10% owner | Buy | 588,235 | $17.00 | $10.0M | Form 4 |
| Aug 6, 2026 | Sanofi10% owner | Buy | 300,000 | $17.00 | $5.1M | Form 4 |
| Aug 6, 2026 | Green Jeremy10% owner | Buy | 600,000 | $17.00 | $10.2M | Form 4 |
| Aug 6, 2026 | venBio Global Strategic Fund IV, L.P.10% owner | Buy | 382,352 | $17.00 | $6.5M | Form 4 |
| Aug 6, 2026 | GOLDMAN SACHS ASSET MANAGEMENT, L.P. | Buy | 500,000 | $17.00 | $8.5M | Form 4 |
| Aug 6, 2026 | GOLDMAN SACHS & CO. LLC | Buy | 500,000 | $17.00 | $8.5M | Form 4 |
| Aug 5, 2026 | WALSH COLINDirector | Buy | 85,000 | $21.00 | $1.8M | Form 4 |
| Aug 5, 2026 | WALSH COLINDirector | Sale | 105,807 | $21.28 | $2.3M | Form 4 |
| Aug 5, 2026 | WALSH COLINDirector | Buy | 85,000 | $21.00 | $1.8M | Form 4 |
| Aug 5, 2026 | WALSH COLINDirector | Sale | 105,807 | $21.28 | $2.3M | Form 4 |
| Aug 5, 2026 | GOLDMAN SACHS ASSET MANAGEMENT, L.P. | Buy | 85,000 | $21.00 | $1.8M | Form 4 |
| Aug 5, 2026 | GOLDMAN SACHS ASSET MANAGEMENT, L.P. | Sale | 105,807 | $21.28 | $2.3M | Form 4 |
| Aug 5, 2026 | GOLDMAN SACHS & CO. LLC | Buy | 85,000 | $21.00 | $1.8M | Form 4 |
| Aug 5, 2026 | GOLDMAN SACHS & CO. LLC | Sale | 105,807 | $21.28 | $2.3M | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Deep Track Capital, LPSCHEDULE 13G, 1 filing Aug 12, 202613
- Frazier Life Sciences Public Fund, L.P.SCHEDULE 13D, 1 filing Aug 11, 202614
SEC filer profile
How Attovia Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARAttovia Therapeutics, Inc.1
- CIK0002058707
- Employer ID (EIN)92-15105741
- Filer statusNon-accelerated filer<br>smaller reporting company<br>emerging growth company1
- Incorporated inDelaware1
- Fiscal year endsDecember 311
- Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address1091 Industrial Road, San Carlos, CA 940701
- Phone51039950011
- Shares outstanding45,651,262 as of Aug 31, 202615
- On EDGAR sinceDec 19, 20251
- Filings56 in all: 3 (19), 4 (14), 4/A (4), 3/A (2), 8-K (2), DRS/A (2), S-1/A (2), 10-Q (1)1
All 18 form types
144 (1), 424B4 (1), 8-A12B (1), CERT (1), DRS (1), EFFECT (1), S-1 (1), S-8 (1), SCHEDULE 13D (1), SCHEDULE 13G (1)
- Latest filingsQuarterly report (10-Q) Sep 2, 2026
Latest 8-K (8-K) Sep 2, 2026
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5SEC EDGARAaron Royston, Board member
- 6SEC EDGARAngie You, Board member
- 7SEC EDGARJames N. Topper, Board member
- 8SEC EDGARJohn W. Smither, Board member
- 9SEC EDGARMitchell Gold, Board member
- 10SEC EDGARResults of operations
- 11SEC EDGARBylaws or fiscal year changed
- 12NasdaqNasdaq calendar
- 13
- 14
- 15